Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health—the BLADE study
Journal of Endocrinological Investigation - Trang 1-9 - 2023
Tóm tắt
It is not clear whether changes in body composition induced by androgen deprivation therapy (ADT) in prostate cancer (PC) patients are uniform or vary in the different body districts and whether regional lean body mass (LBM) and fat body mass (FBM) could have an impact on bone health. To prospectively evaluate the regional changes in LBM and FBM in PC patients submitted to degarelix; to explore the relationship of regional body composition and bone mineral density (BMD) and bone turnover markers. 29 consecutive non metastatic PC patients enrolled from 2017 to 2019. FBM, LBM and bone mineral density (BMD) evaluated by dual-energy x-ray absorptiometry (DXA) at baseline and after 12-month of ADT. Alkaline phosphate (ALP) and C-terminal telopeptide of type I collagen (CTX) assessed at baseline, 6 and 12 months. All patients underwent degarelix administration. T-test or sign test and Pearson or Spearman test for continuous variables were used when indicated. Median percent increase in FBM ranged from + 14.5% in trunk to + 25.4% in the left leg after degarelix. LBM changes varied from + 2% in the trunk to − 4.9% in the right arm. LBM in both arms and legs and their variations after degarelix directly correlated with ALP and inversely correlated with CTX. Lean mass of limbs, trunk and legs significantly correlated with BMD of the hip, lean mass of the trunk significantly correlated with spine BMD. These are post-hoc analysis of a prospective study and this is the main limitation. an heterogeneous change in body composition among body district is observed after ADT and bone turnover is influenced by lean mass and its variation. A supervised physical activity is crucial to maintain general physical performance and preserving bone health.
Tài liệu tham khảo
Parker C et al (2020) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9):1119–1134
Berruti A, Dalla Volta A (2018) Resistance to hormonal therapy in prostate cancer. Handb Exp Pharmacol 249:181–194
Deepika F et al (2022) Baseline testosterone predicts body composition and metabolic response to testosterone therapy. Front Endocrinol (Lausanne) 13:915309
Berruti A et al (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167(6):2361–2367 (discussion 2367)
Haseen F et al (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 4(2):128–139
Atkins JL, Wannamathee SG (2020) Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. Br J Nutr 124(10):1102–1113
Buttigliero C et al (2015) The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome. Endocrine 50(1):223–230
Palumbo C et al (2022) Effect of Degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade study. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgac489
Dalla Volta A et al (2020) Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. J Clin Oncol 38(29):3363–3366
Klotz L et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102(11):1531–1538
Ponti F et al (2019) Aging and imaging assessment of body composition: from fat to facts. Front Endocrinol (Lausanne) 10:861
Shao W et al (2022) The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: an update systematic review and meta-analysis. PLoS ONE 17(2):e0263918
Palumbo C et al (2021) Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study. Prostate Cancer Prostatic Dis 24(3):852–859
Zhang J et al (2015) Associations of fat mass and fat distribution with bone mineral density in Chinese obese population. J Clin Densitom 18(1):44–49
Glass NA et al (2018) Does visceral or subcutaneous fat influence peripheral cortical bone strength during adolescence? A longitudinal study. J Bone Miner Res 33(4):580–588
Cavedon V et al (2021) Body composition and bone mineral density in athletes with a physical impairment. PeerJ 9:e11296
Chen H et al (2022) Sarcopenic obesity defined by visceral adiposity was associated with osteoporotic vertebral fracture. Arch Osteoporos 17(1):41
Skalsky AJ et al (2012) Regional and whole-body dual-energy X-ray absorptiometry to guide treatment and monitor disease progression in neuromuscular disease. Phys Med Rehabil Clin N Am 23(1):67–73
Cornford P et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642
Mottet N et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629
Visser M et al (1999) Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study–Dual-Energy X-ray Absorptiometry and Body Composition Working Group. J Appl Physiol 87(4):1513–1520
Buckinx F et al (2018) Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle 9(2):269–278
Messina C et al (2020) Body composition with dual energy X-ray absorptiometry: from basics to new tools. Quant Imaging Med Surg 10(8):1687–1698
Li G et al (2019) Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. J Cell Biochem 120(9):14262–14273
Formenti AM et al (2021) Effects of medical treatment of prostate cancer on bone health. Trends Endocrinol Metab 32(3):135–158
Santini D et al (2020) Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. ESMO Open. https://doi.org/10.1136/esmoopen-2019-000652
Avin KG et al (2015) Biomechanical aspects of the muscle-bone interaction. Curr Osteoporos Rep 13(1):1–8
Vena W et al (2022) Body composition, trabecular bone score and vertebral fractures in subjects with Klinefelter syndrome. J Endocrinol Invest. https://doi.org/10.1007/s40618-022-01901-8
Cheng SH et al (2020) Fat distribution may predict intra- or extra-capsular hip fracture in geriatric patients after falling. Injury 51(2):414–419
Fu X et al (2011) Associations of fat mass and fat distribution with bone mineral density in pre- and postmenopausal Chinese women. Osteoporos Int 22(1):113–119
Kajiki Y et al (2022) Psoas muscle index predicts osteoporosis and fracture risk in individuals with degenerative spinal disease. Nutrition 93:111428